MaaT Pharma, SA
France
97 articles about MaaT Pharma, SA
-
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
-
MaaT Pharma Announces Publication of Results from Completed Phase 1/2 ODYSSEE Clinical Trial in Nature Communications
5/25/2021
MaaT Pharma announced that final results from its Phase 1/2 ODYSSEE clinical trial have been published in the journal, Nature Communications.
-
MaaT Pharma Announces Positive Topline Results from Phase 2 HERACLES Clinical Trial with Lead Microbiome Ecosystem Therapy MaaT013 in Patients with Acute Graft-versus-Host Disease
3/17/2021
MaaT Pharma announced positive topline results from its Phase 2 clinical trial evaluating lead microbiome ecosystem therapy, MaaT013, in a high-risk patient population with grade III-IV steroid-refractory, gastrointestinal-predominant acute graft-versus-host disease.
-
MaaT Pharma to Provide Clinical Data for Lead Microbiome Ecosystem Therapeutic MaaT013 in Intestinal Acute GvHD at Virtual 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT)
3/11/2021
Data from 29 patients in the company’s early access program with MaaT013 as a treatment for gastrointestinal acute Graft-versus-Host Disease will be highlighted in an oral presentation
-
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
-
MaaT Pharma Announces First Positive DSMB Safety Review for Phase Ib CIMON Trial Testing Its Microbiome Ecosystem Therapy Capsule Formulation in AML Patients
12/22/2020
Independent Data Safety and Monitoring Board (DSMB) recommends continuing CIMON study and initiating dosing of second patient cohort
-
MaaT Pharma Presents Positive Updated Results with its Lead Microbiome Biotherapeutic MaaT013 in Intestinal Acute GvHD at ASH 2020 Annual Meeting
12/7/2020
Data showed MaaT013 to be safe and effective in 29 heavily pre-treated and immunocompromised gastrointestinal (GI) acute Graft-versus-Host-Disease (aGvHD) patients
-
MaaT Pharma Announces Series B Extension and Final Closing with Total of €25 Million ($29.5 Million)
12/1/2020
Additional proceeds will be used primarily to accelerate the development of a proprietary fermentation process to design targeted, full-ecosystem, large-scale, microbiome-based products
-
MaaT Pharma to Provide Data Update for Lead Microbiome Biotherapeutic in Oral Presentation at 62nd American Society of Hematology (ASH) Annual Meeting
11/26/2020
Treatment of 29 acute gastrointestinal Graft-versus-Host-Disease patients with full-ecosystem microbiome restoration biotherapeutic MaaT013 reported safe, demonstrating positive impact
-
MaaT Pharma Treats First Acute Myeloid Leukemia Patient in Phase 1 Clinical Trial to Evaluate Capsule Formulation of Microbiome Restoration Biotherapeutic
11/12/2020
Study will evaluate safety, dosing regimen and activity of MaaT033 in patients with acute myeloid leukemia receiving intensive chemotherapy
-
BioSpace Global Roundup, Sept. 3
9/3/2020
Biopharma and life science companies from across the globe provide updates on their pipelines and businesses. -
MaaT Pharma Announces Positive Data for Its Lead Microbiome Biotherapeutic MaaT013 in Intestinal Acute Graft-versus-Host-Disease at the Virtual 46th Annual Meeting of the EBMT
8/31/2020
MaaT Pharma Announces Positive Data for Its Lead Microbiome Biotherapeutic MaaT013 in Intestinal Acute Graft-versus-Host-Disease at the Virtual 46 th Annual Meeting of the EBMT -- Clinical data was gathered from eleven patients with gastrointestinal (GI) aGvHD treated with MaaT013, MaaT Pharma’s full-ecosystem microbiota biotherapeutic, as part of a compassionate use program -- -- MaaT013 provided positive impact with satisfactory safety profile in al
-
MaaT Pharma to Announce Clinical Data with its Lead Microbiota Biotherapeutic in Intestinal Acute GvHD at Virtual 46th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT)
8/28/2020
Data from the Company’s compassionate use program with MaaT013 as a treatment in patients with intestinal acute Graft-versus-Host-Disease will be highlighted in an e-poster presentation
-
MaaT Pharma Appoints Claude Bertrand, Servier’s Executive Vice President of R&D, as Independent Board Member and Welcomes New Chief Medical Officer John Weinberg
7/16/2020
MaaT Pharma announced the appointment of Claude Bertrand, PharmD, PhD, as an independent member to the company’s Board of Directors and welcomes John Weinberg, MD, as new Chief Medical Officer.
-
MaaT Pharma Appoints Savita Bernal as Chief Business Officer
5/28/2020
MaaT Pharma strengthens management team adding strategic business development and product marketing expertise
-
MaaT Pharma Announces Formation of Its GvHD-focused Scientific Advisory Board to Support Development of Microbiome Restoration Therapeutics in Hemato-oncological Indications
5/12/2020
MaaT Pharma announced today the appointment of leading international experts in the field of microbiome research, hemato-oncology, infectiology, immunology, pharmacology, and clinical trial methodology to its newly-formed Scientific Advisory Board (SAB) focused on the treatment of Graft versus Host Disease (GvHD). The SAB will serve as a resource to advise MaaT Pharma on its scientific, regulatory and clinical development
-
BioSpace Global Roundup: Feb. 6
2/6/2020
Pharma and life science companies from across the globe provide updates on their pipelines and businesses. -
MaaT Pharma Announces €18 Million Series B Financing Round to Support Further Clinical Development of Microbiome Biotherapeutics
2/5/2020
Funding enables expansion of clinical program to include additional cancer indications and development of a capsule formulation of MaaT Pharma’s full-ecosystem therapeutic
-
MaaT Pharma Announces the Presentation of Positive Data with Its Lead Microbiome Biotherapeutic in Intestinal-Predominant Acute Graft-versus-Host-Disease at the ASH 2019 Annual Meeting
12/7/2019
MaaT Pharma’s full-ecosystem microbiota biotherapeutic provided positive impact with satisfactory safety profile in eight patients with advanced stages of GI aGvHD
-
MaaT Pharma to Present Initial Results with its Lead Microbiota Biotherapeutic in Intestinal GvHD at 61st American Society of Hematology (ASH) Annual Meeting
11/6/2019
Pooled-donor full ecosystem microbiota biotherapeutic reported safe in eight patients treated